New combo aims to fight lung cancer without chemo
NCT ID NCT04013542
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this chemo-free approach can shrink tumors and improve outcomes. About 21 participants will receive the combination treatment and be monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab and nivolumab (immunotherapy drugs) plus radiation therapy
What this could lead to
If it works, this could point toward a new treatment option for locally advanced non-small cell lung cancer that avoids chemotherapy.
What could go wrong
This is a very early phase 1 trial with only 21 participants, so results may not apply broadly. Immunotherapy can cause serious immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.